Journal article
Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
Abstract
Eltrombopag has been shown to be noninferior to intravenous immunoglobulin (IVIG) for improving perioperative platelet counts in patients with immune thrombocytopenia (ITP) in a randomized trial; thus, cost is an important factor for treatment and policy decisions. We used patient-level data from the trial to conduct a cost-effectiveness analysis comparing perioperative eltrombopag 50 mg daily starting dose, with IVIG 1 or 2 g/kg (according to …
Authors
Kaur MN; Arnold DM; Heddle NM; Cook RJ; Hsia C; Blostein M; Jamula E; Sholzberg M; Lin Y; Kassis J
Journal
Blood Advances, Vol. 6, No. 3, pp. 785–792
Publisher
American Society of Hematology
Publication Date
February 8, 2022
DOI
10.1182/bloodadvances.2021005627
ISSN
2473-9529